Navidea Biopharmaceuticals (NAVB +4.7%) trades up today after reporting results of its 2013 Annual Meeting of Stockholders held earlier today. NAVB made a series of presentations to shareholders highlighting Lymphoseek's U.S commercialization and indication expansion development activities, selection of a specialty pharma partner for its commercialization in Europe, and initiation of a pivotal NAV4694 Phase 3 registration study.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs